- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT04959266
A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib
A Phase I, Open-label, Non-randomised Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor), Rifampicin (a CYP3A4 Inducer), and Omeprazole (a Proton Pump Inhibitor) on the Pharmacokinetics of a Single Oral Dose of Adavosertib in Patients With Advanced Solid Tumours
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Yksityiskohtainen kuvaus
The study will include 3 arms consisting of a screening period of up to 28 days (Day -28 to Day -1), an intervention period (12 days for arm A, 17 days for arm B, and 12 days for arm C), and a follow-up end of treatment [EOT] visit (within 3 days after a 4-day washout period relative to the last dose of adavosertib).
Arm A of this study follows a non-randomised, open-label, 2-intervention design. Patients will receive the following 2 study interventions: a single oral dose of adavosertib alone, and a single oral dose of adavosertib administered concomitantly with itraconazole.
Arm B of this study follows a non-randomised, open-label, 2-intervention design. Patients will receive the following 2 study interventions: a single oral dose of adavosertib alone, and a single oral dose of adavosertib administered concomitantly with rifampicin.
Arm C of this study follows a non-randomised, open-label, 2-intervention design. Patients will receive the following 2 study interventions: a single oral dose of adavosertib alone, and a single oral dose of adavosertib administered concomitantly with omeprazole.
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Vaihe 1
Yhteystiedot ja paikat
Opiskelupaikat
-
-
-
Madrid, Espanja, 28041
- Research Site
-
Malaga, Espanja, 29010
- Research Site
-
-
-
-
Oregon
-
Portland, Oregon, Yhdysvallat, 97213
- Research Site
-
-
Texas
-
Austin, Texas, Yhdysvallat, 78758
- Research Site
-
Dallas, Texas, Yhdysvallat, 75230
- Research Site
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Histologically or cytologically documented, locally advanced or metastatic solid tumour, excluding lymphoma, for which standard therapy does not exist or has proven ineffective or intolerable.
- Eastern Cooperative Oncology Group performance status score of 0 or 1.
- Predicted life expectancy ≥ 12 weeks.
- Patients must have normal organ and marrow function at baseline, within 7 days prior to study drug administration.
- Males and females of childbearing potential who agree to use contraceptive measures must be consistent with clinical study protocol.
Exclusion Criteria:
- Persistent toxicities (Common Terminology Criteria for Adverse Events [CTCAE] Grade > 2) caused by previous anticancer therapy, excluding alopecia and CTCAE Grade 2 peripheral neuropathy.
- Refractory nausea and vomiting, chronic gastrointestinal disease, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption, distribution, metabolism, or excretion of adavosertib, itraconazole, rifampicin, and omeprazole.
- Any significant cardiac diseases currently or within the last 6 months such as: (a) unstable angina pectoris (b) acute myocardial infarction, congestive heart failure (c) conduction abnormality not controlled with pacemaker or medication (d) significant ventricular or supraventricular arrhythmias.
Any of the following:
- History or current evidence of congenital long QT syndrome;
- concomitant medications known to prolong QT interval or history of medicationrelated QT prolongation.
- Known to have tested positive for human immunodeficiency virus or active tuberculosis infection.
- Known active hepatitis infection, positive hepatitis C antibody, hepatitis B virus surface antigen or hepatitis B virus core antibody, at screening.
- Any evidence of diseases (such as severe or uncontrolled systemic diseases, including uncontrolled hypertension, renal transplant, active infections, and active bleeding diseases) which prohibit participating in the study.
- Spinal cord compression or brain metastases unless asymptomatic, stable, and not requiring steroids for at least 4 weeks prior to start of study intervention.
- Receipt of live virus and live bacterial vaccines whilst the patient is receiving the study intervention and during the 30-day follow-up period. Inactivated flu vaccines are permitted.
- Use of an anti-cancer treatment drug ≤ 21 days (≤ 6 weeks for nitroureas or mitomycin C) or use of an investigational product within 5 half-lives prior to the first dose of adavosertib.
- Patient uses drugs that are sensitive to CYP3A4 substrates or CYP3A4 substrates with a narrow therapeutic index, or are moderate to strong inhibitors/inducers of CYP3A4 which cannot be discontinued 2 weeks or 5 halflives (whichever is longer) prior to Day 1 of dosing.
- Patients with a known hypersensitivity to adavosertib, itraconazole, rifampicin, and omeprazole or any of the excipients of the product.
- Currently pregnant (confirmed with positive pregnancy test) or breast-feeding.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Muut
- Jako: Ei satunnaistettu
- Inventiomalli: Crossover-tehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
---|---|
Kokeellinen: Arm A
Patients will receive a single oral dose of adavosertib alone, and a single oral dose of adavosertib concomitantly with itraconazole.
|
Patients will receive a single dose of Adavosertib orally in arm A, B, and C.
Patients will receive Itraconazole orally once daily for 7 days in arm A.
|
Kokeellinen: Arm B
Patients will receive a single oral dose of adavosertib alone, and a single oral dose of adavosertib concomitantly with rifampicin.
|
Patients will receive a single dose of Adavosertib orally in arm A, B, and C.
Patients will receive Rifampicin orally once daily for 13 days in arm B.
|
Kokeellinen: Arm C
Patients will receive a single oral dose of adavosertib alone, and a single oral dose of adavosertib concomitantly with omeprazole.
|
Patients will receive a single dose of Adavosertib orally in arm A, B, and C.
Patients will receive Omeprazole orally once daily for 5 days in arm C.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Ratios of geometric means of Cmax (maximum observed plasma concentration) when administered in combination with itraconazole/rifampicin/omeprazole relative to adavosertib alone
Aikaikkuna: Arm A: Days 1-4 and 9-12; Arm B: Days 1-4 and 14-17; Arm C: Days 1-4 and 9-12
|
Assessment of the effect of itraconazole (arm A)/rifampicin (arm B)/omeprazole (arm C) on the Cmax of adavosertib following oral dosing in patients with advanced solid tumours.
|
Arm A: Days 1-4 and 9-12; Arm B: Days 1-4 and 14-17; Arm C: Days 1-4 and 9-12
|
Ratios of geometric means of AUCinf (Area under plasma concentration-time curve from time zero to infinity) when administered in combination with itraconazole/rifampicin/omeprazole relative to adavosertib alone
Aikaikkuna: Arm A: Days 1-4 and 9-12; Arm B: Days 1-4 and 14-17; Arm C: Days 1-4 and 9-12
|
Assessment of the effect of itraconazole (arm A)/rifampicin (arm B)/omeprazole (arm C) on the AUCinf of adavosertib following oral dosing in patients with advanced solid tumours.
|
Arm A: Days 1-4 and 9-12; Arm B: Days 1-4 and 14-17; Arm C: Days 1-4 and 9-12
|
Ratios of geometric means of AUClast (Area under the plasma concentration-time curve from zero to time of last quantifiable concentration) when administered in combination with itraconazole/rifampicin/omeprazole relative to adavosertib alone
Aikaikkuna: Arm A: Days 1-4 and 9-12; Arm B: Days 1-4 and 14-17; Arm C: Days 1-4 and 9-12
|
Assessment of the effect of itraconazole (arm A)/rifampicin (arm B)/omeprazole (arm C) on the AUClast of adavosertib following oral dosing in patients with advanced solid tumours.
|
Arm A: Days 1-4 and 9-12; Arm B: Days 1-4 and 14-17; Arm C: Days 1-4 and 9-12
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Summary of Adavosertib plasma concentrations with time
Aikaikkuna: Arm A: Days 1-4 and 9-12; Arm B: Days 1-4 and 14-17; Arm C: Days 1-4 and 9-12
|
Assessment of pharmacokinetics (PK) for adavosertib when administered alone and in combination with itraconazole (arm A) /rifampicin (arm B) /omeprazole (arm C).
|
Arm A: Days 1-4 and 9-12; Arm B: Days 1-4 and 14-17; Arm C: Days 1-4 and 9-12
|
Descriptive statistics of Cmax
Aikaikkuna: Arm A: Days 1-4 and 9-12; Arm B: Days 1-4 and 14-17; Arm C: Days 1-4 and 9-12
|
Assessment of Cmax for adavosertib when administered alone and in combination with itraconazole (arm A) /rifampicin (arm B) /omeprazole (arm C).
|
Arm A: Days 1-4 and 9-12; Arm B: Days 1-4 and 14-17; Arm C: Days 1-4 and 9-12
|
Descriptive statistics of AUCinf
Aikaikkuna: Arm A: Days 1-4 and 9-12; Arm B: Days 1-4 and 14-17; Arm C: Days 1-4 and 9-12
|
Assessment of AUCinf for adavosertib when administered alone and in combination with itraconazole (arm A) /rifampicin (arm B) /omeprazole (arm C).
|
Arm A: Days 1-4 and 9-12; Arm B: Days 1-4 and 14-17; Arm C: Days 1-4 and 9-12
|
Descriptive statistics of AUClast
Aikaikkuna: Arm A: Days 1-4 and 9-12; Arm B: Days 1-4 and 14-17; Arm C: Days 1-4 and 9-12
|
Assessment of AUClast for adavosertib when administered alone and in combination with itraconazole (arm A) /rifampicin (arm B) /omeprazole (arm C).
|
Arm A: Days 1-4 and 9-12; Arm B: Days 1-4 and 14-17; Arm C: Days 1-4 and 9-12
|
Descriptive statistics of tmax (Time to reach maximum observed concentration following drug administration)
Aikaikkuna: Arm A: Days 1-4 and 9-12; Arm B: Days 1-4 and 14-17; Arm C: Days 1-4 and 9-12
|
Assessment of tmax for adavosertib when administered alone and in combination with itraconazole (arm A) /rifampicin (arm B) /omeprazole (arm C).
|
Arm A: Days 1-4 and 9-12; Arm B: Days 1-4 and 14-17; Arm C: Days 1-4 and 9-12
|
Descriptive statistics of λz (Terminal elimination rate constant)
Aikaikkuna: Arm A: Days 1-4 and 9-12; Arm B: Days 1-4 and 14-17; Arm C: Days 1-4 and 9-12
|
Assessment of λz for adavosertib when administered alone and in combination with itraconazole (arm A) /rifampicin (arm B) /omeprazole (arm C).
|
Arm A: Days 1-4 and 9-12; Arm B: Days 1-4 and 14-17; Arm C: Days 1-4 and 9-12
|
Descriptive statistics of t½λz (Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve)
Aikaikkuna: Arm A: Days 1-4 and 9-12; Arm B: Days 1-4 and 14-17; Arm C: Days 1-4 and 9-12
|
Assessment of t½λz for adavosertib when administered alone and in combination with itraconazole (arm A) /rifampicin (arm B) /omeprazole (arm C).
|
Arm A: Days 1-4 and 9-12; Arm B: Days 1-4 and 14-17; Arm C: Days 1-4 and 9-12
|
Descriptive statistics of CL/F (Apparent total body clearance of drug from plasma after extravascular administration)
Aikaikkuna: Arm A: Days 1-4 and 9-12; Arm B: Days 1-4 and 14-17; Arm C: Days 1-4 and 9-12
|
Assessment of CL/F for adavosertib when administered alone and in combination with itraconazole (arm A) /rifampicin (arm B) /omeprazole (arm C).
|
Arm A: Days 1-4 and 9-12; Arm B: Days 1-4 and 14-17; Arm C: Days 1-4 and 9-12
|
Descriptive statistics of Vss/F (Volume of distribution (apparent) at steady state following extravascular administration)
Aikaikkuna: Arm A: Days 1-4 and 9-12; Arm B: Days 1-4 and 14-17; Arm C: Days 1-4 and 9-12
|
Assessment of Vss/F for adavosertib when administered alone and in combination with itraconazole (arm A) /rifampicin (arm B) /omeprazole (arm C).
|
Arm A: Days 1-4 and 9-12; Arm B: Days 1-4 and 14-17; Arm C: Days 1-4 and 9-12
|
Descriptive statistics of Vz/F (Apparent volume of distribution during the terminal phase after extravascular administration)
Aikaikkuna: Arm A: Days 1-4 and 9-12; Arm B: Days 1-4 and 14-17; Arm C: Days 1-4 and 9-12
|
Assessment of Vz/F for adavosertib when administered alone and in combination with itraconazole (arm A) /rifampicin (arm B) /omeprazole (arm C).
|
Arm A: Days 1-4 and 9-12; Arm B: Days 1-4 and 14-17; Arm C: Days 1-4 and 9-12
|
Descriptive statistics of Ctrough (Observed lowest drug concentration reached before the next dose is administered)
Aikaikkuna: Arm A: Days 9-11; Arm B: Days 14-17; Arm C: Day 9
|
Assessment of Ctrough for itraconazole, rifampicin and omeprazole when administered in combination with adavosertib.
|
Arm A: Days 9-11; Arm B: Days 14-17; Arm C: Day 9
|
Number of patients with serious and non-serious adverse events
Aikaikkuna: From screening to end of study [within 30 (±7) days of last adavosertib dose]
|
Assessment of the safety and tolerability of adavosertib when dosed with itraconazole (arm A), rifampicin (arm B), and omeprazole (arm C).
|
From screening to end of study [within 30 (±7) days of last adavosertib dose]
|
Yhteistyökumppanit ja tutkijat
Sponsori
Yhteistyökumppanit
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
- Huumeiden fysiologiset vaikutukset
- Farmakologisen vaikutuksen molekyylimekanismit
- Infektiota estävät aineet
- Nukleiinihapposynteesin estäjät
- Entsyymin estäjät
- Ruoansulatuskanavan aineet
- Hormonit, hormonikorvikkeet ja hormoniantagonistit
- Bakteerien vastaiset aineet
- Sytokromi P-450 CYP3A:n estäjät
- Sytokromi P-450 -entsyymin estäjät
- Leprostaattiset aineet
- Hormoniantagonistit
- Sytokromi P-450 entsyymin indusoijat
- Antifungaaliset aineet
- Steroidisynteesin estäjät
- Haavoja ehkäisevät aineet
- Protonipumpun estäjät
- Sytokromi P-450 CYP3A:n indusoijat
- Tuberkulaariset aineet
- 14-alfa-demetylaasi-inhibiittorit
- Antibiootit, antituberkulaariset
- Sytokromi P-450 CYP2B6:n indusoijat
- Sytokromi P-450 CYP2C8:n indusoijat
- Sytokromi P-450 CYP2C19-indusoijat
- Sytokromi P-450 CYP2C9:n indusoijat
- Rifampiini
- Itrakonatsoli
- Omepratsoli
- Adavosertib
Muut tutkimustunnusnumerot
- D601HC00006
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD-jaon aikakehys
IPD-jaon käyttöoikeuskriteerit
When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the
Disclosure Statements at:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Edistyneet kiinteät kasvaimet
-
Millennium Pharmaceuticals, Inc.Valmis
-
Novartis PharmaceuticalsValmiscMET-dysregulated Advanced Solid TumorsYhdysvallat, Espanja, Italia, Bulgaria, Yhdistynyt kuningaskunta, Ranska, Tanska
-
Shanghai Pudong HospitalUTC Therapeutics Inc.PeruutettuMesoteliinipositiiviset Advanced Refractory Solid TumorsKiina
-
Novartis PharmaceuticalsValmiscMET-dysregulated Advanced Solid TumorsYhdysvallat, Italia, Espanja, Yhdistynyt kuningaskunta, Kreikka, Belgia, Itävalta, Tšekki
-
Novartis PharmaceuticalsValmiscMET Dysegulation Advanced Solid TumorsItävalta, Tanska, Ruotsi, Yhdistynyt kuningaskunta, Espanja, Saksa, Alankomaat, Yhdysvallat
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdRekrytointiKRAS G12C Mutant Advanced Solid TumorsKiina
-
AmgenAktiivinen, ei rekrytointiKRAS p.G12C Mutant Advanced Solid TumorsYhdysvallat, Ranska, Kanada, Espanja, Belgia, Korean tasavalta, Itävalta, Australia, Unkari, Kreikka, Saksa, Japani, Romania, Sveitsi, Brasilia, Portugali
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Tuntematon
-
Novartis PharmaceuticalsNantCell, Inc.LopetettuPIK3CA-mutaation kehittyneet kiinteät kasvaimet | PIK3CA Amplified Advanced Solid TumorsEspanja, Belgia, Yhdysvallat, Kanada
Kliiniset tutkimukset Adavosertib
-
AstraZenecaParexelLopetettuEdistyneet kiinteät kasvaimetYhdistynyt kuningaskunta
-
AstraZenecaValmisEdistyneet kiinteät kasvaimetJapani
-
Merck Sharp & Dohme LLCValmis
-
Merck Sharp & Dohme LLCLopetettu
-
AstraZenecaValmisMunasarjasyöpä | Paikallisesti edenneet kiinteät kasvaimet | Metastaattiset kiinteät kasvaimetYhdysvallat
-
AstraZenecaParexelLopetettuEdistyneet kiinteät kasvaimetYhdistynyt kuningaskunta, Yhdysvallat
-
Samsung Medical CenterValmisPienisoluinen keuhkosyöpäKorean tasavalta
-
AstraZenecaParexelValmisKohdun seroosisyöpäYhdysvallat, Italia, Espanja, Ranska, Kanada
-
Dana-Farber Cancer InstituteAstraZenecaAktiivinen, ei rekrytointiKohdun syöpäYhdysvallat
-
Samsung Medical CenterLopetettu